Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United States Brent Oil Fund LP (BNO) Price & Performance

ACADIA Pharmaceuticals Inc.
United States Brent Oil Fund LP

Price performance

Price movement over the last 24 hours

Key statistics

ACADIA Pharmaceuticals Inc. vs United States Brent Oil Fund LP — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while United States Brent Oil Fund LP trades at $43.81. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, United States Brent Oil Fund LP nearer its low. Which is the better fit depends on your goals.

ACADBNO
Market Cap
$4.49B
Sector
HealthCommodities - Energy
52-Week High
$28.06$60.13
52-Week Low
$20.06$27.20
Enterprise Value
$3.69B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.

Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.

United States Brent Oil Fund LP

BNO trades at $39.94, up 0.68% on the day, amid a bearish technical backdrop with moving averages signaling caution and oscillators neutral. Recent news highlights oil price volatility driven by Middle East tensions and supply disruptions, though fundamental financial ratios are unavailable. The stock faces resistance near $40 with support at $39.

The outlook remains clouded by geopolitical risks and oil market volatility, with limited fundamental data. Upside depends on sustained oil price recovery, but downside risks from supply surges or demand weakness persist. Investors should weigh technical bearishness against external catalysts.

Returns comparison

Trailing returns across standard periods

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About United States Brent Oil Fund LP

BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.

Read more on BNO